N-[1-(4-chlorophenyl)-1-ethylpropyl]-7,7-dimethyl-5-phenyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide hydrochloride | 1268168-20-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡唑并嘧啶类
• 英文名称: N-[1-(4-chlorophenyl)-1-ethylpropyl]-7,7-dimethyl-5-phenyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide hydrochloride
• 英文别名: N-[3-(4-chlorophenyl)pentan-3-yl]-7,7-dimethyl-5-phenyl-5,6-dihydro-4H-pyrazolo[1,5-a]pyrimidine-3-carboxamide;hydrochloride
• CAS: 1268168-20-2
• 化学式: C₂₆H₃₁ClN₄O*ClH
• 分子量: 487.472
• InChiKey: UJFJDQJDFFNHLI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.7
• 重原子数：
  33
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  59
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  N-(1-(4-chlorophenyl)-1-ethylpropyl)-7,7-dimethyl-5-phenyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide 在 盐酸 作用下， 以 水 、 乙酸乙酯 为溶剂， 以71%的产率得到N-[1-(4-chlorophenyl)-1-ethylpropyl]-7,7-dimethyl-5-phenyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide hydrochloride
  参考文献：
  名称：

  刺激脉冲状甲状旁腺激素分泌的新型和有效的口服活性钙敏感受体拮抗剂的发现：四氢吡唑并嘧啶衍生物的合成与构效关系

  摘要：

  作为我们对新型钙敏感受体（CaSR）拮抗剂的研究的一部分，该拮抗剂可作为口服骨合成代谢药物发挥作用，我们最近报道了具有金刚烷基1b的四氢吡唑并嘧啶衍生物的发现，该衍生物具有强大的CaSR拮抗活性。为了探索该煅烧同源物的潜力，我们在四氢吡唑并嘧啶环的3-位引入了宝石-二烷基苄基，通过模仿金刚烷基的亲脂性和蓬松性而形成了金刚烷基的生物等排体。针对溶解度和代谢稳定性改善的优化导致了化合物9e的发现，当向正常大鼠口服时，该化合物可刺激PTH的短暂分泌。此外，复合9e在骨质减少卵巢切除的大鼠模型中被证明是完全有效的。

  DOI：

  10.1021/jm101452x

文献信息

• Calcium receptor modulating compound and use thereof
  申请人：Yasuma Tsuneo

  公开号：US20060079536A1

  公开（公告）日：2006-04-13

  There is provided a calcium receptor modulator comprising a compound of the formula (I): wherein ring A is an optionally substituted 5- to 7-membered ring; ring B is an optionally substituted 5- to 7-membered heterocyclic ring; X 1 is CR 1 , CR 1 R 2 , N or NR 13 ; X 2 is N or NR 3 ; Y is C, CR 4 or N, Z is CR 5 , CR 5 R 6 , N or NR 7 ; Ar is an optionally substituted cyclic group; R is H, an optionally substituted hydrocarbon group, etc.; and is a single bond or a double bond; R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and R 13 are independently H, an optionally substituted hydrocarbon group; or a salt thereof or a prodrug thereof. Compounds of the formula (II) and (III): wherein ring A is an optionally substituted 5- to 7-membered ring; Q is C, CR 5 or N; R 8 , R 9 , R 10 , R 11 and R 12 are independently, H, an optionally substituted hydrocarbon group, etc., or a salt thereof are also provided. Also specify X 1 , R 3 , R 1 , Y and X 3 in formula (II) and (III) as before.

  提供了一种含有式(I)化合物的钙受体调节剂：其中，环A是可选取代的5-至7-成员环；环B是可选取代的5-至7-成员杂环；X1是CR1、CR1R2、N或NR13；X2是N或NR3；Y是C、CR4或N；Z是CR5、CR5R6、N或NR7；Ar是可选取代的环状基团；R是H、可选取代的碳氢基团等；是单键或双键；R1、R2、R3、R4、R5、R6、R7和R13独立地是H、可选取代的碳氢基团；或其盐或前药。还提供了式(II)和(III)化合物：其中，环A是可选取代的5-至7-成员环；Q是C、CR5或N；R8、R9、R10、R11和R12独立地是H、可选取代的碳氢基团等；或其盐。在式(II)和(III)中，X1、R3、R1、Y和X3的指定与之前相同。
• SUBSTITUTED PYRAZOLO[1,5-A] PYRIMIDINES AS CALCIUM RECEPTOR MODULATING AGENTS
  申请人：Takeda Pharmaceutical Company Limited

  公开号：US20140155416A1

  公开（公告）日：2014-06-05

  There is provided a calcium receptor modulator comprising a compound of the formula (I): wherein ring A is an optionally substituted 5- to 7-membered ring; ring B is an optionally substituted 5- to 7-membered heterocyclic ring; X 1 is CR 1 , CR 1 R 2 , N or NR 13 ; X 2 is N or NR 3 ; Y is C, CR 4 or N, Z is CR 5 , CR 5 R 6 , N or NR 7 ; Ar is an optionally substituted cyclic group; R is H, an optionally substituted hydrocarbon group, etc.; and is a single bond or a double bond; R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and R 13 are independently H, an optionally substituted hydrocarbon group; or a salt thereof or a prodrug thereof. Compounds of the formula (II) and (III): wherein ring A is an optionally substituted 5- to 7-membered ring; Q is C, CR 5 or N; R 8 , R 9 , R 10 , R 11 and R 12 are independently, H, an optionally substituted hydrocarbon group, etc., or a salt thereof are also provided. Also specify X 1 , R 3 , R 1 , Y and X 3 in formula (II) and (III) as before.

  提供了一种含有式(I)化合物的钙受体调节剂，其中环A是可选取代的5-至7元环；环B是可选取代的5-至7元杂环；X1是CR1，CR1R2，N或NR13；X2是N或NR3；Y是C，CR4或N，Z是CR5，CR5R6，N或NR7；Ar是可选取代的环状基团；R是H，可选取代的烃基团等；表示单键或双键；R1、R2、R3、R4、R5、R6、R7和R13独立地是H，可选取代的烃基团；或其盐或前药。还提供了式(II)和(III)的化合物：其中环A是可选取代的5-至7元环；Q是C，CR5或N；R8、R9、R10、R11和R12独立地是H，可选取代的烃基团等，或其盐。同样指定式(II)和(III)中的X1、R3、R1、Y和X3如前。
• SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINES AS CALCIUM RECEPTOR MODULATING AGENTS
  申请人：Yasuma Tsuneo

  公开号：US20090215746A1

  公开（公告）日：2009-08-27

  There is provided a calcium receptor modulator comprising a compound of the formula (I): wherein ring A is an optionally substituted 5- to 7-membered ring; ring B is an optionally substituted 5- to 7-membered heterocyclic ring; X 1 is CR 1 , CR 1 R 2 , N or NR 13 ; X 2 is N or NR 3 ; Y is C, CR 4 or N, Z is CR 5 , CR 5 R 6 , N or NR 7 ; Ar is an optionally substituted cyclic group; R is H, an optionally substituted hydrocarbon group, etc.; and is a single bond or a double bond; R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and R 13 are independently H, an optionally substituted hydrocarbon group; or a salt thereof or a prodrug thereof. Compounds of the formula (II) and (III): wherein ring A is an optionally substituted 5- to 7-membered ring; Q is C, CR 5 or N; R 8 , R 9 , R 10 , R 11 and R 12 are independently, H, an optionally substituted hydrocarbon group, etc., or a salt thereof are also provided. Also specify X 1 , R 3 , R 1 , Y and X 3 in formula (II) and (III) as before.

  提供了一种包含式(I)化合物的钙受体调节剂，其中环A是可选取代的5-至7-成员环；环B是可选取代的5-至7-成员杂环；X1是CR1、CR1R2、N或NR13；X2是N或NR3；Y是C、CR4或N，Z是CR5、CR5R6、N或NR7；Ar是可选取代的环状基团；R是H、可选取代的碳氢基团等；和是单键或双键；R1、R2、R3、R4、R5、R6、R7和R13独立地是H、可选取代的碳氢基团；或其盐或前药。还提供了式(II)和(III)化合物：其中环A是可选取代的5-至7-成员环；Q是C、CR5或N；R8、R9、R10、R11和R12独立地是H、可选取代的碳氢基团等，或其盐。同时，如前所述，还指定式(II)和(III)中的X1、R3、R1、Y和X3。
• EP1572113A4
  申请人：——

  公开号：EP1572113A4

  公开（公告）日：2006-11-22
• CALCIUM RECEPTOR MODULATING COMPOUND AND USE THEREOF
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP1572113A2

  公开（公告）日：2005-09-14